Loading...
Loading...
STSA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 11.9M |
| Operating I/L | -23.6M |
| Other Income/Expense | 0.5M |
| Interest Income | 0.5M |
| Pretax | -23.1M |
| Income Tax Expense | -0.6M |
| Net Income/Loss | -22.5M |
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel therapeutic products for the acute treatment of migraines. Their lead product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, currently in SUMMIT Phase 3 efficacy trials. This product can be self-administered using a proprietary pre-filled, single-use nasal delivery device. Satsuma Pharmaceuticals, Inc. generates revenue through the development and potential commercialization of STS101 and other therapeutic products for migraine treatment.
